TW202327571A - 精神作用醫藥及其用於治療精神及神經病狀及病症之用途 - Google Patents

精神作用醫藥及其用於治療精神及神經病狀及病症之用途 Download PDF

Info

Publication number
TW202327571A
TW202327571A TW111129588A TW111129588A TW202327571A TW 202327571 A TW202327571 A TW 202327571A TW 111129588 A TW111129588 A TW 111129588A TW 111129588 A TW111129588 A TW 111129588A TW 202327571 A TW202327571 A TW 202327571A
Authority
TW
Taiwan
Prior art keywords
disorder
disorders
anxiety
methyl ketone
dose
Prior art date
Application number
TW111129588A
Other languages
English (en)
Chinese (zh)
Inventor
布萊克 曼德爾
馬汀 斯托哥尼
珍妮佛 露易絲 史密特
馬克斯 史利格
Original Assignee
美商優越治療股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商優越治療股份有限公司 filed Critical 美商優越治療股份有限公司
Publication of TW202327571A publication Critical patent/TW202327571A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
TW111129588A 2021-08-06 2022-08-05 精神作用醫藥及其用於治療精神及神經病狀及病症之用途 TW202327571A (zh)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US202163230237P 2021-08-06 2021-08-06
US63/230,237 2021-08-06
US202163240113P 2021-09-02 2021-09-02
US63/240,113 2021-09-02
US202163255706P 2021-10-14 2021-10-14
US63/255,706 2021-10-14
US202263325757P 2022-03-31 2022-03-31
US63/325,757 2022-03-31
US202263328343P 2022-04-07 2022-04-07
US63/328,343 2022-04-07

Publications (1)

Publication Number Publication Date
TW202327571A true TW202327571A (zh) 2023-07-16

Family

ID=85156410

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111129588A TW202327571A (zh) 2021-08-06 2022-08-05 精神作用醫藥及其用於治療精神及神經病狀及病症之用途

Country Status (10)

Country Link
US (6) US11707446B2 (https=)
EP (1) EP4380588A4 (https=)
JP (1) JP2024530007A (https=)
KR (1) KR20240072133A (https=)
AU (1) AU2022325135A1 (https=)
CA (1) CA3227360A1 (https=)
IL (1) IL310334A (https=)
MX (1) MX2024001654A (https=)
TW (1) TW202327571A (https=)
WO (1) WO2023015154A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024254190A2 (en) * 2023-06-06 2024-12-12 Transcend Therapeutics, Inc. Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders
US12295937B2 (en) 2021-08-06 2025-05-13 Transcend Therapeutics, Inc. Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders
US12343326B2 (en) 2021-08-06 2025-07-01 Transcend Therapeutics, Inc. Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders
MX2024001654A (es) 2021-08-06 2024-06-28 Transcend Therapeutics Inc Medicamentos psicoactivos y su uso para el tratamiento de enfermedades y trastornos psiquiatricos y neurologicos.
KR20240165982A (ko) * 2022-03-31 2024-11-25 트랜센드 테라퓨틱스 인코퍼레이티드 향정신성 의약품과 정신 및 신경계 병태 및 장애를 치료하기 위한 이의 용도

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996039133A1 (en) * 1995-06-06 1996-12-12 Neurobiological Technologies, Inc. Novel n-substituted-2-amino-3',4'-methylene-dioxypropiophenones
US8575194B1 (en) 2004-08-31 2013-11-05 Jack William Schultz Treatment methods of cognitive, emotional and mental ailments and disorders
US20120108510A1 (en) 2010-05-20 2012-05-03 Emory University Methods of improving behavioral therapies
EP2931291B1 (en) 2012-12-11 2021-10-20 The McLean Hospital Corporation Xenon treatment as an adjunct to psychotherapy for psychiatric disorders
WO2017151980A1 (en) 2016-03-03 2017-09-08 Segreti Louis M Cannabis-based bioactive formulations and methods for use thereof
WO2021257500A1 (en) 2020-06-17 2021-12-23 Lobe Sciences Ltd. Methods and compositions for treating mild traumatic brain injury, post-traumatic stress disorder and mild traumatic brain injury with post traumatic stress disorder
JP2024512796A (ja) * 2021-04-01 2024-03-19 テラン バイオサイエンシーズ インク． サイケデリック薬およびセロトニン受容体調節因子に関する方法と組成物
MX2024001654A (es) 2021-08-06 2024-06-28 Transcend Therapeutics Inc Medicamentos psicoactivos y su uso para el tratamiento de enfermedades y trastornos psiquiatricos y neurologicos.
EP4426685A4 (en) * 2021-11-05 2026-01-07 Terran Biosciences Inc Isotopic salts, crystalline forms, stereoisomers of methylone and ethylone and their methods of use

Also Published As

Publication number Publication date
US20240058301A1 (en) 2024-02-22
WO2023015154A1 (en) 2023-02-09
US20240293357A1 (en) 2024-09-05
EP4380588A1 (en) 2024-06-12
US11969407B2 (en) 2024-04-30
US20230054211A1 (en) 2023-02-23
US12059402B2 (en) 2024-08-13
US20250255846A1 (en) 2025-08-14
CA3227360A1 (en) 2023-02-09
KR20240072133A (ko) 2024-05-23
US11707446B2 (en) 2023-07-25
JP2024530007A (ja) 2024-08-14
US12233046B2 (en) 2025-02-25
IL310334A (en) 2024-03-01
EP4380588A4 (en) 2025-10-08
US20260083699A1 (en) 2026-03-26
MX2024001654A (es) 2024-06-28
US20230338333A1 (en) 2023-10-26
AU2022325135A1 (en) 2024-02-08

Similar Documents

Publication Publication Date Title
US11969407B2 (en) Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders
JP2022529353A (ja) 神経認知障害、慢性疼痛を治療し、炎症を低減させる方法
JP2020514313A (ja) 脆弱ｘ症候群の治療のためのプリドピジンの使用
CN116940362A (zh) 在慢性ssri方案后使用苯二氮䓬增加对裸盖菇素的敏感性
US10195165B2 (en) Methods of treating Prader-Willi syndrome
TW202345789A (zh) 精神作用醫藥及其用於治療精神及神經病狀及病症之用途
US20250221957A1 (en) Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders
US12343326B2 (en) Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders
US12295937B2 (en) Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders
HK40112015A (zh) 精神作用药物及其用於治疗精神和神经病状和病症的用途
CN118434416A (zh) 精神作用药物及其用于治疗精神和神经病状和病症的用途
US20250332139A1 (en) Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders
HK40120411A (zh) 精神作用药物及其用於治疗精神和神经病状和病症的用途
WO2024254190A2 (en) Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders
AU2024284688A1 (en) Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders
JP2024508372A (ja) 注意欠陥／多動性障害の治療又は予防に使用するための化合物
KR20260053276A (ko) 향정신성 의약품과 정신 및 신경계 병태 및 장애를 치료하기 위한 이의 용도
US20260091028A1 (en) Method of treating amyotrophic lateral sclerosis with pridopidine
WO2025248468A1 (en) Use of tyk2/jak1 inhibitors to treat amyloid-related imaging abnormalities (aria)